Molecular targeting delivers. Light decides where to activate.
GenLumina is developing an ultra-small, light-activated payload designed to add an independent spatial control layer to targeted cancer therapies. The payload can be linked to antibodies, peptides or ligands and remains inactive until illuminated at the treatment site.
We are the "D" - the drug - in ADCs and PDCs.
Targeting biology determines which cells the medicine reaches. GenLumina adds a separate light switch intended to control when and where the payload becomes active. This creates a new design option alongside today's systemically active payloads.
Three layers of control.
The platform combines molecular recognition, intracellular delivery and local light activation. Each layer has a distinct role in controlling treatment.
Targeting biology guides delivery.
An antibody, peptide or ligand can be selected around a relevant cancer target and indication.
An ultra-small payload reaches the cell.
DNA-encapsulated silver nanoclusters of approximately 2–3 nm are designed for cellular and intracellular delivery.
Light provides the local switch.
Illumination at the treatment site activates the payload and initiates a local cytotoxic effect.
One payload platform. Multiple partner programmes.
GenLumina is building a payload, licensing and R&D platform, not a single-target oncology company. Partners can combine the platform with targeting biology and indication priorities relevant to their own pipelines.
Partner-selected targeting
Evaluate antibodies, peptides or ligands around the biology that matters to a partner's pipeline.
Partner-specific proof-of-concept
Conjugate and test each partner molecule against separately agreed technical and biological decision criteria.
Licensing-led development
Successful programmes can progress toward indication- and territory-specific licensing while GenLumina retains the underlying platform.
What GenLumina offers partners.
The commercial model follows the development stage. Pharma and biotech partners can already evaluate the payload with their own targeting molecules. In the clinical phase, GenLumina can also work with medtech partners to connect tumor imaging with local light activation.
Bring the targeting molecule. Validate the combination.
A partner brings an antibody, peptide or ligand from its own pipeline. GenLumina provides the light-activated payload, conjugation know-how and a focused partner-specific proof-of-concept.
A successful PoC can lead to separately negotiated indication- and territory-specific development rights, while GenLumina retains ownership of the underlying platform.
Turn tumor imaging into image-guided treatment.
In the clinical phase, GenLumina can work with medtech partners whose imaging platforms are already used in hospitals. The opportunity is to add a dedicated light-activation capability to an established imaging workflow.
GenLumina contributes the payload, activation knowledge and IP. The medtech partner contributes the installed imaging platform, device expertise and clinical workflow.
GenLumina's IP strategy is designed to support separately agreed programmes and licensing rights. The Netherlands patent is granted, with international patent applications including Europe, the United States, China and Japan.
From platform proof to in-vivo validation.
The next value step is to strengthen the safety and efficacy evidence required for partner decisions and later regulatory development.
Patented platform
Patent protection covers the core light-activated nanocluster approach, with international patent applications in key markets.
In-vitro proof-of-concept
Activity has been demonstrated in targeted and conjugated approaches across 2D and 3D cancer models.
In-vivo safety and efficacy
Current work focuses on the preclinical evidence needed to support partner selection and regulatory preparation.
Every year of delay matters.
Our purpose is to help make cancer more controllable and treatment less burdensome. We are building the evidence and partnerships needed to move a new therapeutic option toward patients without losing sight of accessibility and healthcare impact.
One platform. Different ways to contribute.
Whether you bring targeting biology, clinical technology, scientific expertise or mission-aligned capital, the next step should be clear within one click.
Build a programme around the GenLumina platform.
Explore a partner-specific PoC, licensing route or future image-guided co-development opportunity.
Partner with us → Investors & impact financeFund the next evidence step.
Explore impact lending, venture capital and strategic financing routes supporting preclinical validation and partner readiness.
Explore investment → Researchers & talentHelp translate the science.
Discuss research collaboration, specialist expertise or joining the team.
Contact GenLumina →GenLumina is in preclinical development. References to potential therapeutic benefits, licensing structures and future medtech integration describe the intended development and partnering model and remain subject to further preclinical, clinical, regulatory and commercial validation.